Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 4/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.33 |
| ▸ | MGLL | Q99685 | 3/20 | 0.33 |
| ▸ | NPC1L1 | Q9UHC9 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 3/20 | 0.32 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.32 |
| ▸ | FASN | P49327 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1750496 | 0.88 | BACE1 (0.40) | RIPK1BACE1RORC | |
| SCHEMBL1752202 | 0.86 | BACE1 (0.39) | RIPK1BACE1LMNA | |
| SCHEMBL2299336 | 0.85 | NAMPT (0.33) | LMNANAMPTHTR2BALKMGLL | |
| SCHEMBL2299402 | 0.85 | NAMPT (0.36) | LMNANAMPTHTR2BALKMGLL | |
| SCHEMBL1750080 | 0.85 | BACE1 (0.41) | RIPK1BACE1 | |
| SCHEMBL1752110 | 0.83 | RIPK1 (0.42) | RIPK1NAMPTHTR2BMGLL | |
| SCHEMBL3045877 | 0.83 | RIPK1 (0.42) | RIPK1NAMPTHTR2BMGLL | |
| SCHEMBL3033937 | 0.83 | RIPK1 (0.42) | RIPK1NAMPTHTR2BMGLL | |
| SCHEMBL1750125 | 0.83 | RIPK1 (0.41) | RIPK1NAMPTALKMGLLFASN | |
| SCHEMBL1750671 | 0.82 | RIPK1 (0.41) | RIPK1NAMPTMGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968585-B2 | Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 | ELI LILLY AND COMPANY (US) | 2011-06-28 | — | — | US | disclosed |
| EP-2035379-B1 | INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | LILLY CO ELI (US) | 2010-06-16 | — | — | EP | disclosed |
| US-20090099180-A1 | INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | ELI LILLY AND COMPANY | 2009-04-16 | — | — | US | disclosed |
| EP-2035379-A2 | INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | Eli Lilly & Company (US) | 2009-03-18 | — | — | EP | disclosed |
| WO-2007127763-A2 | INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | ELI LILLY AND COMPANY (US) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099180-A1 | INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | HSD11B1, HSD11B2, HSD3B1 | RIPK1 2806/4885BACE1 155/4885LMNA 2527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.